Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 9.00
Ask: 9.50
Change: 0.10 (1.09%)
Spread: 0.50 (5.556%)
Open: 9.15
High: 9.25
Low: 9.15
Prev. Close: 9.15
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

Thu, 26th Aug 2021 12:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Caerus Mineral Resources PLC - copper and gold explorer with licenses in Cyprus - Alongside copper-gold exploration and development company Bezant Resources PLC, Caerus notes the Troulli project in Cyprus has been selected as the first project for a joint-venture. "The joint review, which will also have input from Jubilee Metals Group PLC, will cover all waste recycling and hard rock VMS projects within the Caerus portfolio with an emphasis on Troulli as the first joint venture project between Caerus and Bezant," Caerus explains. Says diamond drilling and resource estimate programme to be agreed at project.

----------

TomCo Energy PLC - oil project development in US focused on using new technology to unlock unconventional hydrocarbon resources - Buys Valkor LLC's 50% interest in the Greenfield Energy LLC joint-venture. TomCo now owns all of Greenfield. Will fund the acquisition through a deferred issue of 592.8 million shares, currently 29% of the company's capital.

----------

Power Metal Resources PLC - metal exploration and development in Africa - Says total of 19 holes completed at first phase of diamond drilling exploration programme at Silver Peak project in Canada. "All cores are being logged, catalogued and split by independent geological consultants prior to being sent to ALS Canada Ltd in Vancouver, British Columbia, for accredited laboratory assay analysis," Power Metal adds. Establishes new vehicle named Silver Peak Resources Ltd in anticipation of public listing of project, or to allow for a third party acquisition. At Tati in Botswana, crews have been mobilised for phase 2 work programme on the gold and nickel greenstone belt.

----------

Aura Energy Ltd - Australia-based minerals company - Completes gravity survey at Tasiast South tenements in Mauritania. "The gravity data allows better definition of geology, the identification of structures likely to be of relevance to gold deposition and the possibility of direct detection of sulphide mineralisation on the nickel/cobalt targets," Aura says.

----------

Westmount Energy Ltd - invests in companies which operate in oil & gas related industries - Notes beginning of drilling at Sapote-1, located in Canje block in offshore Guyana. Westmount holds a 7.2% interest in Canje, which is operated by Exxon Mobil Corp. Exxon's Esso Exploration & Production Guyana Ltd has a 35% stake, TotalEnergies SE unit TotalEnergies E&P Guyana BV also holds 35%.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Secures USD24 million supply and distribution pact with AMC Holdings Inc for its phytomedicine products. The deal lasts three years. "This is MGC Pharma's first USA supply agreement dedicated to taking MGC's pharmaceutical phytocannabinoid products into the world's largest healthcare market," company adds. For the first year, AMC will pay MGC USD750,000 and a letter of credit for a further USD2.3 million.

----------

Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Says UK's Medicines & Healthcare Products Regulatory Authority approves plans to kick off first-in-human trial of Modi-1 vaccine which targets cancer cells. "The company expects to enrol patients into the study in the second half of 2021, following ethics committee sign-off. Initial safety and tolerability data from the initial open label portion of the trial could be available from the first half of 2022," Scancell says.

----------

Eden Research PLC - Cirencester-based agricultural chemicals producer - Says Mevalone biofungicide receives green light for use on new crops in Portugal. The product is used to treat Botrytis cinerea, a fungal pathogen. "This latest label extension adds strawberries, raspberries, blueberries, cranberries, kiwi, aubergines and peppers to the label, with product applications being permitted close to the point of harvest," Eden explains.

----------

Bidstack Group PLC - London-based in-game advertising platform - Partners with Motionlab Interactive, the makers of mobile game PDC Darts Match. PDC is the Professional Darts Corp, a darts governing body. "The new game expands Bidstack's stadium vertical and increases the number of sports covered to five different categories (football, tennis, cricket, jiu-jitsu and darts)," Bidstack explains.

----------

D4t4 Solutions PLC - Surrey-based data management company - Says continuing to trade in line with board expectation. "The business is delivering against its key KPIs and is well positioned in its core markets," D4t4 says. Says rolllout of Celebrus Fraud Data platform progresses. Company adds: "D4t4 has also commenced a marketing and PR campaign, particularly focused on raising the profile of Celebrus products in the US market."

----------

Braemar Shipping Services PLC - London-based shipbroker - "Pleased" by performance in first five months of financial year ended February. Braemar says: "Trading has been good across all three of the group's divisions and the breadth of the group's business model, the diversity of the broking operation and the markets in which the group now operates, have insulated the business well from any ongoing pandemic weakness."

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.